Boehringer Ingelheim Aptivus To Get FDA Advisory Committee Review In May
This article was originally published in The Pink Sheet Daily
Executive Summary
Tipranavir will be considered by FDA's Antiviral Drugs Advisory Committee for the treatment of patients with multi-drug-resistant HIV. In clinical trials, use of the protease inhibitor was associated with GI adverse events and elevated triglycerides.